Labcorp Oncology executives say paired germline and somatic testing is becoming increasingly important in precision oncology, reflecting demand for more complete hereditary and tumor-derived biomarker insights. In an executive Q&A, Rebecca Previs and Sarah Young discussed how paired testing improves test access and supports targeted treatment decisions. The interview also highlighted growing use cases for AI in supporting biomarker interpretation and operational workflows, aiming to reduce bottlenecks between ordering, reporting, and clinical action. The message is oriented toward real-world deployment—how testing strategies scale beyond academic settings. For sponsors and diagnostic developers, the discussion signals that reimbursement, interoperability, and clinical utility evaluation will increasingly be judged by how well paired testing informs action across therapy selection and clinical trial matching.